Richard J. Cote is the Joseph R. Coulter Jr. Chair of the Department of Pathology, and Director of the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami Miller School of Medicine. He is a board certified Pathologist, who has served over 20 years in senior academic, consultative, and director/clinical roles with leading universities, hospitals and healthcare enterprises primarily in the area of cancer care.
Dr. Cote obtained degrees in chemistry and biology at the University of California at Irvine, and received his medical degree from the University of Chicago - Pritzker School of Medicine.
Prior to joining the University of Miami in 2009, he was at the University of Southern California Keck School of Medicine as a Professor in the departments of Pathology and Urology. He also served as Director of the Genitourinary Cancer Program, the Laboratory of Immunology and Molecular Pathology, as well as the USC Biomedical Nanoscience Initiative.
Dr. Cote’s research is focused on the elucidation of cellular and molecular pathways of tumor progression and response to therapy. He has special interests in micrometastases detection and characterization and in the pathology of breast and genitourinary tumors. His laboratory is also focused on technology development, where Dr. Cote and his colleagues have developed immunohistochemical and molecular methods, such as antigen retrieval.
Most recently, Dr. Cote and his colleagues at the University of Southern California, Caltech and UC Berkeley have developed nanoscale technologies for cancer diagnostic applications, including bionanosensors for the detection of serum tumor markers, and technologies for the capture and characterization of circulating tumor cells. As a result of these efforts, he established the Biomedical Nanoscience Program at USC and the Dr. John T. Macdonald Biomedical Nanotechnology Institute at the University of Miami for the development of novel diagnostic platforms and targeted therapeutics.
He is the recipient of over $43 million in peer reviewed grant support, and holds numerous patents for cancer related and nanoscale technologies. He has led three of the largest clinical trials in breast, lung and bladder cancer, which were based on discoveries from his research. Dr. Cote is the author of over 300 publications, and participates on numerous scientific advisory boards for both academic and industry related institutions.
Dr. Cote is the founder of several technology based companies, including Impath, Inc., Clarient, Filtini and Sensitini. He is listed in “US News and World report Top 1% of Doctors,” amongst others.
A reception will follow the lecture. Please RSVP at:
Speaker:
Institution:
Location:
